HTA - - Health Technology Assessment Report

Dornase alfa for patients with cystic fibrosis: a review of the clinical efficacy and cost-effectiveness (Structured abstract)

Code: HTA-32014000134 **Year:** 2013 **Date:** 2013 **Author:** CADTH

Study design (if review, criteria of inclusion for studies)

A limited literature search was conducted of key resources, and titles and abstracts of the retrieved publications were reviewed. Full-text publications were evaluated for final article selection according to predetermined criteria (population, intervention, comparator, outcomes, and study designs).

Participants

CF patients with moderate to severe chronic pulmonary disease

Interventions

Dornase alfa (Pulmozyme) - a purified solution for inhalation of recombinant human deoxyribonuclease (rhDNase)

Outcome measures

clinical effectiveness, cost effectiveness

Main results

The literature search produced 136 citations, with no additional studies identified from the grey literature. Of these, 21 were deemed potentially relevant and 3 met the criteria for inclusion in this review: 1 systematic review, 1 randomized controlled trial, and one economic evaluation.

http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32014000134/frame.html

See also

Health Technology Assessment Database

Keywords

Adolescent; Child; Deoxyribonuclease; Airway clearance drugs -expectorants- mucolytic- mucociliary-; hydration; Hypertonic Solutions; Infant; pharmacological_intervention; Respiratory System Agents; Dornase alpha; Pulmozyme; Inhalation OR nebulised; nebuliser;